Weekly Retail Sales Tracker for Solid Tumors - Week Ended June 5

Research evidence excerpt

Weekly Retail Sales Tracker for Solid Tumors - Week Ended June 5

Quick Note

June 14, 2026 Biotechnology

Weekly Retail Sales Tracker for Solid Tumors - Week Ended

Analysts June 5

David Nierengarten, Ph.D.

(415) 274-6862

David.Nierengarten@wedbush.com

Robert Driscoll, Ph.D. In this weekly report we provide updated IQVIA prescription data for select, FDA-

(415) 274-6863 approved branded solid tumor drugs distributed through retail drug channels in the

Robert.Driscoll@wedbush.com U.S. market only, through the Week Ended June 5. This report is meant to serve as

Martin Fan, Ph.D. a guide for evaluating trends in branded retail drug use in the US and should not(213) 688-3404

Martin.Fan@wedbush.com be relied upon for definitive accuracy as a number of dynamics may influence the

Dennis Pak reported numbers.

(415) 263-6647 Key components of the report:Dennis.Pak@wedbush.com

Geoffrey Von Der Ahe ● Script Data by Select Drug Class: In this section we provide a summary of IQVIA

(628) 223-0517 script data for select drugs organized by pertinent drug class or indication. Drug

geoffrey.vonderahe@wedbush.com classes or indications we’re currently tracking include:

■ BRAF inhibitors

■ FGFR inhibitors

■ HER2 inhibitors

■ EGFR inhibitors

■ VEGFR inhibitors

■ MET inhibitors

■ RET inhibitors

■ MEK inhibitors

■ CDK4/6 inhibitors

■ PD-1/PD-L1 inhibitors

■ ALK/ROS1 inhibitors

● Drug Snapshots: This section provides a one-page snapshot of select FDA

approved drugs for solid tumors. Information includes basic identifying

information (manufacturer, drug target/mechanism, route of administration

and dosing schedule, approval history, drug label, and current monthly price),

as well as weekly retail channel sales estimates (TRx MBS Dollars), New (NRx),